Immuneering (IMRX) Cash from Investing Activities (2020 - 2026)
Immuneering (IMRX) posted quarterly Cash from Investing Activities of -$63.1 million for Q1 2026, down 704995.3% year-over-year from N/an in Q1 2025, and up 28.91% quarter-over-quarter from -$88.7 million in Q4 2025.
Immuneering (IMRX) Cash from Investing Activities (2020 - 2026) Analysis & Trends
Immuneering's Cash from Investing Activities history runs 7 years deep, the most recent figure standing at -$63.1 million for Q1 2026.
- In Q1 2026, Cash from Investing Activities fell 704995.3% year-over-year to -$63.1 million; the TTM figure through Mar 2026 stood at -$151.8 million (down 3115.8% YoY), while the FY2025 annual figure was -$88.7 million, down 435.69% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at -$63.1 million, up from -$88.7 million in the prior quarter.
- The five-year high for Cash from Investing Activities was $22.2 million in Q2 2022, with the low at -$88.7 million in Q4 2025.
- The 5-year median for Cash from Investing Activities is $3.1 million (2023), against an average of -$4.5 million.
- The sharpest annual moves came in 2022 and 2026: Cash from Investing Activities jumped 111852.97% in 2022, then slumped 704995.3% in 2026.
- Immuneering's Cash from Investing Activities stood at $8.2 million in 2022, then plunged by 61.57% to $3.1 million in 2023, then soared by 75.26% to $5.5 million in 2024, then tumbled by 1715.84% to -$88.7 million in 2025, then gained by 28.91% to -$63.1 million in 2026.
- Business Quant data shows IMRX's Cash from Investing Activities at -$63.1 million in Q1 2026, -$88.7 million in Q4 2025, and -$7255.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -1.66 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -49.35 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 19.77 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -229.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -363.46 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Immuneering | 327.37 Mn | 327.37 Mn | - | 10.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.48 Mn |
| Jun 30, 2026 | 10.48 Mn |
| Mar 31, 2026 | -63.07 Mn |
| Mar 31, 2026 | -63.07 Mn |
| Dec 31, 2025 | -88.72 Mn |
| Dec 31, 2025 | -88.72 Mn |
| Sep 30, 2025 | -7,255.00 |
| Sep 30, 2025 | -7,255.00 |
| Jun 30, 2025 | -2,116.00 |
| Jun 30, 2025 | -2,116.00 |
| Mar 31, 2025 | -8,945.00 |
| Mar 31, 2025 | -8,945.00 |
| Dec 31, 2024 | 5.49 Mn |
| Dec 31, 2024 | 5.49 Mn |
| Sep 30, 2024 | -5.42 Mn |
| Sep 30, 2024 | -5.42 Mn |
| Jun 30, 2024 | 4.97 Mn |
| Jun 30, 2024 | 4.97 Mn |
| Mar 31, 2024 | 21.39 Mn |
| Mar 31, 2024 | 21.39 Mn |